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ABSTRACT
The mechanism behind the positive action of introns
upon transcription and the biological significance of
this positive feedback remains unclear. Functional
ablation of splice sites within an HIV-derived env
cDNA significantly reduced transcription that was
rescued by a U1 snRNA modified to bind to the
mutated splice donor (SD). Using this model we
further characterized both the U1 and pre-mRNA
structural requirements for transcriptional enhance-
ment. U1 snRNA rescued as a mature Sm-type
snRNP with an intact stem loop II. Position and
sequence context for U1-binding is crucial
because a promoter proximal intron placed up-
stream of the mutated SD failed to rescue transcrip-
tion. Furthermore, U1-rescue was independent of
promoter and exon sequence and is partially
replaced by the transcription elongation activator
Tat, pointing to an intron-localized block in
transcriptional elongation. Thus, transcriptional
coupling of U1 snRNA binding to the SD may
licence the polymerase for transcription through
the intron.
INTRODUCTION
The splicing of eukaryotic mRNA transcripts coincides
with transcriptional elongation and the two processes
are tightly coupled and coordinated by the C-terminal
domain (CTD) of RNA Polymerase (Pol) II (1). The
CTD is a long and unstructured domain containing,
in humans, 52 repeats of the consensus heptapeptide
YS2PTS5PS7 (2). Tightly regulated post-translational
modiﬁcation of this unit is termed the CTD code (3) and
aﬀects the binding and activity of RNA processing factors.
For example, phosphorylation at Ser 5 by the CDK7
subunit of the initiation factor TFIIH (4) recruits
the capping enzyme (5) and facilitates promoter clearance
(6). After CDK7 action, Ser 2 of the CTD is
phosphorylated by the CDK9 subunit of the positive elon-
gation factor P-TEFb promoting the release of Pol II from
promoter proximal pausing by clearance of NELF (7) and
phosphorylation of DSIF (8). Truncation of the CTD
reduces splicing eﬃciency (9) and the ability of the
phosphorylated CTD to bind a suite of splicing factors
(10,11) may facilitate exon deﬁnition in higher eukaryotes
by tethering the exons to Pol II during transcription
(12,13). Thus the CTD of Pol II represents a crucial
interface between the transcription machinery and regula-
tion of mRNA splicing.
A number of studies provide evidence for a reciprocal
inﬂuence of splicing upon transcription. It was known
early that introns within trans-genes of transgenic mice
increase transcription from 10- to 100-fold (14). Later
the splice donor (SD) was shown to be responsible for
this eﬀect (15–17) and requires the binding of U1 small
nuclear RNA (snRNA) (18,19), a factor better known for
its crucial role in initiation of spliceosome formation.
Engineering the SD to a site more distal from the
promoter reduces the positive eﬀect on mRNA accumula-
tion (15,16) which may be due to a reduction in 50 cap
proximal recruitment of U1 snRNA (20) or spatial
interactions with re-initiating Pol II. Splicing can also
activate elongation processivity as the splicing factor
SC35 enhances elongation of some mammalian genes by
interacting with P-TEFb (21) while spliceosomal U small
nuclear ribonucleoproteins (snRNPs) can associate with
the elongation factor Tat-SF1 to increase transcription
from Adenovirus, HIV and b-globin templates in HeLa
nuclear extract (22). Moreover, P-TEFb is dispensable
for transcription of intronless genes like U2 snRNA and
histone H2b (23) suggesting intron-containing genes
require highly processive elongation.
Following demonstration that the promoter proximal
SD1 in an HIV-derived, intron-containing transcript
enhanced transcription (16), an in vitro interaction
between U1 snRNA and Cyclin H was shown to
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to SD1, SD4 is essential for eﬃcient accumulation of
mRNA transcripts from a transiently transfected HIV
env-derived cDNA (18). Nuclear run on analysis from
an integrated env cDNA construct showed that SD4
increases transcription (17). U1snRNA enhancement
of transcription is not speciﬁc to viral genes as mutation
of the SD in the ﬁrst intron of the bi-intronic b-globin
gene triggers a similar transcriptional defect (17). But
U1 snRNA binding is not a universal requirement for eﬃ-
cient gene expression as many cDNAs can be expressed
without an intron.
We have examined the requirements for U1 snRNA
enhancement of transcription using U1 snRNA-
mediated rescue of Env expression from an HIV-1 env
cDNA construct with mutated SD4. In addition to
proper biogenesis through Sm binding, stem loop II was
vital for U1-rescue. Local pre-mRNA sequence context
for U1 snRNA binding was also crucial as a promoter
proximal intron failed to rescue transcription of the
splice mutant. The ability of U1 snRNA to facilitate eﬃ-
cient transcription was independent of promoter and exon
sequence and could be replaced by the HIV-1 transcrip-
tion elongation activator Tat. We therefore propose that
U1 snRNA engagement overcomes a checkpoint for elon-
gation present in the intron.
MATERIALS AND METHODS
Plasmid construction
The plasmid pHIV-Env has been previously described
(25). pCMV-Env and pCMV-Rev were made by
inserting the BssHII-BlpI fragment from pHIV-Env and
pNLrev1 (25) into pHIS-HIV-B (26) respectively. pCMV
(NoIntron)-Env was created by cutting pCDNA3
(Invitrogen) with NcoI+AseI, blunt ending then inserting
this 248-nt fragment into pCMV-Env which had been cut
with NcoI+NotI and end-ﬁlled. pCMV-Tat was derived
by inserting the PstI-BamHI fragment from pCMV-Tat2x
described in (25) into pCMV-Env. K51A from pTat K51A
(27) was introduced into pCMV-Tat using MfeI and
BamHI. pCMV-Empty was made by cutting pCMV-Env
with BssHII+BlpI, end-ﬁlling and re-ligating.
pCMV-GFP was created by inserting the PstI-NotI
fragment from pEGFP-N1 (BD Biosciences Clonetech)
into pCMV-Empty. pHIV-gp140uncGFP was created
using a ‘three-way’ stitch PCR protocol to insert the
GFP-coding sequence in-frame with a truncated
envelope, gp140unc. The 50 fragment used primers
Odp.1124 and Odp.1854 (see Supplementary Table S1
for sequence of these and all primers named in this
study) with template pHIV-Env(unc), ‘unc’ mutation
described in (28). The middle fragment used Odp.1855
and Odp.1856 with template pEGFP-N1. The 30
fragment was made using Odp.1857 and Odp.1665 with
both wild-type and SA7 mutant pHIV-Env templates.
The second round PCR used gel puriﬁed ﬁrst round
PCR fragments in equimolar amounts with primers
Odp.1124 and Odp.1665. This fragment was then
digested with MfeI and BlpI for ligation into either
wild-type or mutSD4 containing pHIV-Env. pCMV-
gp140uncGFP was made by inserting the MfeI-BlpI
fragment from pHIV-gp140uncGFP into pCMV-Env.
pUCB-U1 is described in (29). GFP(SD4SA7) was
created using ‘three-way’ stitch PCR to insert the WT
and mutant SD4-SA7 intron into pCMV-EGFP. The 50
fragment used pCMV-GFP as template and primers
Odp.241 and Odp.1548 or Odp.1745 for the
GFP(SD4SA7) and GFP(mutSD4SA7) constructs, respec-
tively. The middle fragment used Odp.1550 and Odp.1551
on pHIV-Env or Odp.1746 and Odp.1747 on pHIV-Env
containing mutSD4SA7. The 30 fragment used Odp.773
and Odp.1549 or Odp.1748 on pCMV-GFP for the
GFP(SD4SA7) and GFP(mutSD4SA7) constructs respec-
tively. The stitched fragment was digested with PstI and
NotI for insertion into pCMV-GFP. All mutations
introduced by PCR mutagenesis are shown in
Supplementary Table S2.
Cells and transfection
HeLa cells were maintained in Dulbecco’s Modiﬁed Eagle
Medium (Gibco) supplemented with 10% (v/v) heat
inactivated Foetal Bovine Serum (Bovogen), streptomycin
(100U/ml) and penicillin (100U/ml). Totally 2.5 10
5
cells (6-well plates) or 7.5 10
5 cells (T-25 ﬂasks) were
transfected using Lipofectamine
TM 2000 (Invitrogen) as
per the manufacturer’s instructions. Transfections con-
taining 2mg pHIV-Env, also used the following; 20ng
pCMV-Tat, 100ng pCMV-Rev and 1.5mg pUCB-U1 if
indicated in ﬁgure legends. For pCMV-Env, pCMV-Tat
was omitted. Mock transfections contained 2mg
pHIS-Empty. For western blotting, pCMV-EGFP was
included to measure transfection eﬃciency.
Western blotting
Cells harvested 48h post-transfection using trypsin,
washed in PBS and assessed for transfection eﬃciency
by counting the percentage GFP positive cells by
ﬂow cytometry. Transfections were deemed successful
if percentage GFP positive cells was >60% and did not
vary more than 20% between samples. Cell viability was
assessed by 7-AAD staining. Cells were lysed in 50mlo f
buﬀer [1  TTS; 10mM Tris, pH 8.0, 0,5% (v/v) Triton-X
100, 150mM NaCl, 2mM PMSF, 2mg/ml aprotinin]. An
amount of 100mg total protein was resolved using SDS–
PAGE and membranes probed with a monoclonal
antibodies to HIV-1 gp41 (Chessie 8, NIH) or to b-actin
(Sigma-Aldrich).
RNA isolation
Twenty-four hours post-transfection cells were rinsed with
PBS, trypsinized, washed and re-suspended in 320ml cold
CF buﬀer (10mM Tris–HCl pH 7.4, 10mM NaCl, 3mM
MgCl2, 0.5% NP-40, 40U/ml RNasin (Promega), 1mM
DTT). After 10min incubation on ice, cells were
centrifuged at 500 g for 5min at 4 C and RNA extracted
from 300ml with LS Trizol (Invitrogen) according to the
manufacturer’s instructions. The pellet was washed and
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40mM EDTA) and treated as per the cytoplasmic
fraction. This fractionation step strips membrane-bound
polysomes from the nuclear endoplasmic reticulum (NER)
(30). The nuclear pellet was washed then re-suspended
in 200ml of Trizol (Invitrogen). Total RNA extractions
were performed on cell pellets resuspended in Trizol
(Invitrogen).
Northern blotting
RNA samples in formamide were subject to Northern blot
as described previously (31). Probes were made by PCR
incorporation of [a-
32P]dCTP (Perkin Elmer) using the
primers indicated in ﬁgure legends. Probed membranes
were exposed to a phosphorimager screen and visualized
using the FLA 3000, Fuji. Bands were quantiﬁed by Image
Gauge Ver.4.0 (Fujiﬁlm).
RT–PCR
cDNA was made from 1mg of R fraction or Total RNA
with random hexamer and AMV reverse transcriptase
(Promega), according to manufacturer’s instructions,
ampliﬁed by Phusion DNA Polymerase (Finnzymes) to
35 cycles using primers indicated in ﬁgure legends.
Nucleotide sequence of indicated cDNA PCR products
was determined by gel extraction, cloning and sequencing.
Real-time RT–qPCR
An amount of 1ml cDNA was added to Stratagene
Brilliant II FAST SYBR QPCR Master mix with the
appropriate primers (Supplementary Table S3) and
ampliﬁed on a Mx3000P QPCR machine according to
manufacturer’s instructions. Each PCR was run in dupli-
cate along with no RT enzyme and no template controls.
On the same plate three reference gene amplicons;
GAPDH (Acc: NM_002046), YWHAZ (Acc:
NM_003406) and HPRT1 (Acc: NM_000194) were also
ampliﬁed. The geometric average of the relative expression
of these genes was calculated using the algorithm outlined
in (32) and used to normalize expression of 4-kb env
mRNA.
FACS
Thirty-six hours post-transfection, cells were trypsinized,
washed and resuspended in PBS for analysis of GFP
ﬂuorescence by a BD-FACSCalibur cell sorter. Data
was analysed using Weasel v2.5 (Walter & Eliza Hall
Institute, Melbourne, Australia) and the relative
expression measured by multiplying the percentage
mock gated cells with the mean ﬂuorescence of those
gated cells.
RESULTS
The requirement for an active SD for eﬃcient expression
of intron-containing genes has been observed using viral
(15–18,29), mammalian (14,17) and yeast expression
systems (16). In this study, the HIV-1 env mRNA,
previously shown to require the binding of U1 snRNA
for eﬃcient mRNA accumulation (18), was used as a
model to study the role of U1 snRNA in transcription.
Mutations were introduced into pHIV-Env (Figure 1A)
to prevent U1 snRNA binding at the SD4 site (Figure 1B).
This construct expresses HIV Env, Rev and minimal
amounts of Vpu protein (25). The extent of splicing of
the env mRNA was used as a surrogate measure of U1
snRNA binding. Assessment of splicing by RT–PCR
showed cryptic splicing induced by a single mutation at
SD4 (Figure 1D, lane mutSD4). The cryptic donor site,
SD4x, which was previously identiﬁed upon mutation of
SD4 (33) was conﬁrmed by sequencing of the spliced
cDNA product. Inactivating SD4x was complicated by
the overlapping minimal uORF and Vpu start codon
that may inﬂuence Env translation (34). However, we
could prevent the use of SD4x through a series of muta-
tions at SA7 and adjacent cryptic acceptor sites, SA7c, a
and b (35). The AG dinucleotide at SA7, branch point
(BP), and polypyrimidine tract (PPT) which bind
U2AF
35, SF1 (36) and U2AF
65 (37) respectively, were
mutated to prevent formation of the early spliceosome
complex (38). This eﬀectively ablated splicing as shown
by the absence of 2-kb spliced mRNA (Figure 1D). The
cryptic site used by the SA7 mutant was also identiﬁed by
sequencing and was found to be 20nt downstream from
SA7 (Figure 1D).
SD4 and SA7 are used to construct the completely
spliced 2-kb class of mRNAs that express the Rev
protein. Rev binds to the rev responsive element (RRE)
within the SD4-SA7 intron and is necessary for export of
unspliced 4-kb env mRNA (39). Also, Rev has been shown
to inﬂuence mRNA stability (40) and splicing (41) so is
crucial for eﬃcient Env expression. In order to examine
the eﬀects of SD4 upon Env expression whilst maintaining
constant Rev protein we inactivated the Rev ORF within
the env cDNA constructs by introducing a stop codon at
Rev amino acid 38 (R38) (Figure 1E). We tested the
phenotype of this mutation by examining the splicing
and cellular distribution of mRNA. RNA from
transfected cells was fractionated and analysed by
Northern blotting and the integrity of the various frac-
tions conﬁrmed by probing for U6 snRNA [Nuclear
(N)], 7SL [nuclear-associated endoplasmic reticulum (R)]
and mitochondrial tRNA [cytoplasmic (C)] (Figure 1E,
lower panels). The small amounts of U6 snRNA present
in the cytoplasmic fractions probably derive from the
contents of mitotic or nonviable cells. Notably, 4-kb
mRNA was found in the R fraction, consistent with the
cellular biogenesis of the Env glycoprotein which requires
passage through the ER. The R38 mutation caused
nuclear restriction of 4-kb env mRNA and this was
rescued upon co-transfection of pCMV-Rev (Figure 1E),
which showed cytoplasmic accumulation matching that
seen upon transfection of pHIV-Env without the R38
mutation (Supplementary Figure S1). This allowed us to
compare Env expression from R38 modiﬁed wild-type
(WT.R38) and splice site modiﬁed (mutSD4SA7) env
cDNAs with equal amounts of Rev supplied from a
separate plasmid.
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We then aimed to assess the role of U1 snRNA binding in
transcription using a splice mutant env mRNA,
mutSD4SA7, which had access to the same amount of
Rev as the WT.R38 construct but could not bind U1
snRNA and showed reduced levels of nuclear accumula-
tion by northern blot (Supplementary Figure S2). In the
nucleus and co-incident with transcription by Pol II, U1
snRNA binds to the SD through its 50 arm to initiate
Figure 1. Engineering a U1 snRNA dependent expression system using the HIV unspliced env mRNA. (A) Diagram of the pHIV-Env model
construct. An HIV U3 region promoter (grey box) drives transcription through R and U5 regions, all three of which make up the long terminal
repeat (LTR). The cDNA has the SD1/SA4b intron removed and contains two exons, shown in black rectangles and one intron bounded by SD4 and
SA7. The Env (gp160) open reading frame (ORF) expressed from the unspliced mRNA is shown, the Rev ORF expressed from spliced mRNA is also
shown, Vpu and Nef ORFs are present but do not express signiﬁcant protein in this spliced isoform. (B) Mutations made to SD4 shown in red, a
second cryptic SD SD4x overlaps the minimal upstream ORF (uORF) and Vpu start. (C) Use of SD4x was prevented by mutations shown in red at
the 30 splice site, SA7. The branch point (BP), polypyrimidine tract (PPT) and cryptic acceptors were mutated in addition to SA7 itself. All mutations
introduced were silent with respect to the Env-coding sequence. (D) Splice site mutations ablated splicing. RT–PCR using Odp.2 and Odp.40 was
performed on RNA extracted from cells transfected with the indicated mutant. PCR products were extracted from the gel, cloned and sequenced.
Sequence of SA7x is shown to the right. (E) The spliced product of the pHIV-Env transcript makes the Rev protein which controls the export of
unspliced 4-kb mRNA and hence Env protein expression. The amino acid sequence is shown at the SD4/SA7 exon/exon junction. The Rev ORF was
inactivated using a stop codon at Rev amino acid 38. This mutant was assessed by northern blotting of 4-kb (unspliced) and 2-kb (spliced) mRNA
present in nuclear (N), nuclear-associated rough endoplasmic reticulum (R) and cytoplasmic (C) fractions. The 4- and 2-kb probe was made using
Odp.1409 and Odp.1410. Probes were designed to bind to gapdh (Acc: NM_002046) for loading, U6 snRNA (Acc: X07425), 7SL (Acc:NR_002715)
and mitochondrial tRNA
lys (Acc:X93334, tRNA 14) to control for the eﬃciency of N, R and C fractions respectively.
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making a duplex of at least 11nt (42). We modiﬁed the
50 arm of U1 snRNA in the plasmid pUCB-U1 so that
it made 17H-bond contacts with the SD4 mutant
site instead of nine predicted for the binding of
wild-type U1 snRNA to the SD4 mutant (Figure 2A).
Compared to co-transfection of the modiﬁed U1 snRNA
(U1mut50arm) which cannot bind to the WT.R38 env
mRNA, U1 WT 50arm co-transfected with WT.R38
showed a relatively increased proportion of 2-kb mRNA
which may result from enhanced splicing of a target
mRNA with intact splice sites due to over expression of
U1 snRNA from pUCB-U1 (Figure 2B, upper panels).
Unlike the WT.R38 construct, U1mut50arm increased
the SD4SA7 mutant 4-kb env mRNA accumulation in
the nucleus so that levels were equivalent to WT.R38.
The expression and cellular distribution of U1
snRNAmut50arm was validated by real time PCR,
showing an expected nuclear and cytoplasmic distribution
largely un-altered by the presence of SD4SA7 mutant
env mRNA. Also, rescue of mRNA accumulation by the
modiﬁed U1 snRNA did not cause an increase in splicing
as detected by northern blot and the more sensitive RT–
PCR (Figure 2B, lower panels). Thus the enhancement
eﬀect of U1 snRNA on nuclear mRNA accumulation
occurs independently of splicing catalysis.
Finally, the functionality of the mRNA produced from
the U1-rescued SD4SA7 mutant was assessed by detection
of gp160 protein by western blotting. Expression from the
SD4SA7 mutant in the absence of U1 binding was
signiﬁcantly reduced but detectable. The absence of
detectable substrate mRNA in the cytoplasm for this
sample (Figure 2B, upper panel, lane 4) probably results
from reduced sensitivity of cell fractionation and northern
blotting. Importantly, the increase in nuclear accumula-
tion induced by U1mut50arm was suﬃcient to restore
wild-type levels of Env protein (Figure 2B, lane 5, lowest
panel) demonstrating that U1-rescued unspliced mRNA is
Figure 2. U1 snRNA enhances transcription independent of splicing (A) Hydrogen bonding (H-bonding) of U1 snRNA to SD4. The 50arm of
U1 snRNA contacts SD4 through 16 hydrogen-bonds (H-bonds), while mutSD4 makes only nine H-bonds to U1 snRNA. H-bonding was recovered
by co-transfection of a modiﬁed U1 snRNA mutated (shown in large bold font) to make 17H-bond contacts with mutSD4. (B) U1mut50arm rescues
nuclear accumulation of mutSD4SA7 suﬃcient to rescue protein expression in the absence of splicing. Cells were transfected with 2mg of pHIV-Env
with the indicated mutations, 20ng of pCMV-Tat, 100ng of pCMV-Rev and 1.5mg of pUCB-U1 with the indicated modiﬁcation to the 50arm. These
cells were either fractionated and RNA analysed by northern blotting for 4- and 2-kb mRNA and RT–PCR for 2-kb cDNA or they were lysed
and protein analysed by western blotting for Env (gp160). U1mut50arm was also detected in the various RNA fractions using RT–qPCR with
primers speciﬁc to the mutated 50 arm and normalisation to gapdh mRNA as described in the methods. Lanes are as follows, Lane 1—Mock,
Lane 2—WT.R38+WT 50 arm, Lane 3—WT.R38+mut 50 arm. Lane 4—mutSD4SA7+WT 50 arm, Lane 5—mutSD4SA7+WT 50 arm. (C)U 1
snRNA does not enhance mRNA stability. Transcription was inactivated with 5mg/ml of Actinomycin D and 4-kb mRNA levels from mutSD4SA7
in the presence of U1 snRNA WT 50arm ( U1) and U1 snRNA mut50arm (+U1) assessed by RT–QPCR. 4-kb mRNA levels were normalized to the
geometric mean of three reference genes as described in the methods. Error bars represent standard deviation of the mean from three transfections
performed on diﬀerent days.
Nucleic Acids Research,2010, Vol.38, No. 9 3045eﬃciently exported and translated and that U1 snRNA
binding alone and not the generation of an intron is
responsible for diminished env mRNA and protein
synthesis.
Thus U1 snRNA binding is essential for eﬃcient
nuclear mRNA accumulation. It was unclear however if
U1 snRNA was acting to increase transcription and/or
mRNA stability. We assessed the stability of U1-bound
versus U1-unbound mutSD4SA7 env mRNA by halting
transcription using Actinomycin D and measuring the
decay rate of env mRNA by RT–qPCR. U1-bound env
mRNA levels were found to decline more rapidly upon
Actinomycin D treatment compared with U1-unbound
mRNA (Figure 2C), demonstrating that mRNA stability
was not increased by U1 snRNA binding and therefore
not responsible for increased nuclear accumulation,
conﬁrming that U1 snRNA enhances transcription.
The Sm domain and stem loop II are important for
U1 snRNA enhancement of transcription
U1 snRNA exists as a highly structured RNA bound to
proteins forming a small nuclear ribonucleoprotein
(snRNP) (Figure 3A). We mutated the binding sites for
U170k, U1A and Sm to assess the relative importance of
these proteins in enhancement of transcription by U1
snRNA. We used a ﬂuorescent Env-GFP fusion protein
reporter, gp140uncGFP, where the coding sequence of
GFP was placed in-frame with an un-cleaved and
truncated form of Env. The Env protein was truncated
immediately prior to the transmembrane domain to
create a soluble Env analogue and facilitate the correct
folding and ﬂuorescence of GFP. This truncation of Env
does not compromise the rev responsive element (RRE),
which lies between the end of gp120 and gp140, or the
splicing signals at SA7. The gp160 cleavage motif was
mutated to prevent disassociation into gp120 and
gp41-GFP (28). Fluorescence-activated cell sorting
(FACS) of cells transfected with gp140uncGFP containing
the SD4SA7 mutation was used to report the fold-increase
in expression induced by U1 snRNA which could bind to
mutSD4SA7 env mRNA through mut50arm. This enabled
a quantitative assessment of mutations made to the
U1 snRNA body. The wild-type U1 body with mutant
50 arm increased expression from the SD4SA7 mutant
reporter by 2.4-fold (2.4±0.2, n=4) (Figure 3B), con-
ﬁrming the western blot data (Figure 2B, lowest panel,
compare lanes 4 and 5).
During the biogenesis of U1 snRNA, Sm proteins
assemble on the U1 snRNA in the cytoplasm acting as
an adapter for Importin-b mediated transport of the
mature U1 snRNA into the nucleus (43). Sm binds to
the single-stranded uridine tract in the presence of a
conserved adenosine (44). When the assembly of the Sm
core was blocked using the mutations shown in Figure 3A,
Env expression of the SD4SA7 mutant could not be
rescued (Figure 3B), indicating that U1 snRNA acts in
the nucleus as a mature U1 snRNP to increase transcrip-
tion. This failure to rescue expression was not due to
toxicity induced by over expression of the mutant U1
snRNA as cell viability by 7-AAD staining was unaﬀected
(Supplementary Figure S3).
Mutations made to the U170k-bound stem loop I were
based upon previously described modiﬁcations that
prevent the binding of in vitro transcribed U1snRNA to
Figure 3. U1 snRNA enhancement of transcription requires the Sm
domain and stem loop II (A) U1 snRNA secondary structure and
location of U170k, U1A, U1C and Sm proteins in the small
ribonucleoprotein (snRNP). Mutations to disrupt binding of U170k,
U1A, Sm are shown in red as well as the deletion made to stem
loop II in blue. (B) Sm domain and stem loop II are important for
U1 snRNA rescue. Wild-type U1 snRNA and the four U1 snRNA
body (nt 12–164) mutants with either a wild-type or 50arm (nt 1–11)
mutant were co-transfected with a gp140uncGFP reporter (shown) con-
taining the SD4SA7 mutation in addition to 20ng of pCMV-Tat and
100ng of pCMV-Rev. Values represent the mean of the fold diﬀerence
between the wild-type and mut50arm from four transfections performed
on diﬀerent days. Error bars represent the standard deviation of
the mean.
3046 Nucleic Acids Research, 2010,Vol.38, No. 9U170k in HeLa nuclear extracts (45). The secondary
structure of U1 snRNA, as predicted using M-fold
RNA-folding software (46) (Supplementary Figure S4),
was preserved to ensure binding of SMN for proper U1
snRNA maturation (47). Upon transfection, mutations to
the binding site for U170k did not signiﬁcantly aﬀect
rescue of mutSD4SA7 by U1mut50arm (2.0±0.5, n=4)
(Figure 3B), suggesting that the U170k-binding site does
not play an important role in transcriptional enhancement
by U1 snRNA.
Point mutations made to the U1A-binding site on stem
loop II were also based on in vitro binding data (48).
Purines at positions 1, 4 and 6 of the loop sequence are
critical for binding (49) however mutations at these posi-
tions did not signiﬁcantly aﬀect rescue of mutSD4SA7
expression in our system (1.7±0.3, n=4) (Figure 3B).
In contrast, the complete deletion of stem loop II (SII),
shown previously to disrupt the binding of Cyclin H
in vitro (24), resulted in a signiﬁcant decrease in Env
rescue implicating this stem loop in the mechanism of
U1 snRNA enhancement of transcription.
Heterologous promoter and upstream intron do not alter
the requirement for U1 snRNA binding at SD4
Expression of Env protein from the U1 snRNA binding
WT.R38 cDNA was compared to the SD4SA7 mutant,
which fails to engage U1 snRNA, using constructs with
an alternative promoter and upstream heterologous
intron. We ﬁrst exchanged the HIV U3 promoter with
the Cytomegalovirus (CMV) immediate early promoter.
In the presence of a non-HIV promoter, Env expression
was reduced 3-fold by the splice site mutations
demonstrating that the requirement for active splice sites
to recruit U1 snRNA is not speciﬁc to the HIV promoter
(Figure 4A).
We investigated if expression from the SD4SA7 mutant
construct could be rescued by inclusion of a promoter
proximal intron consisting of the SD from CMV intron
A with a strong U1 snRNA-binding site and the SA from
murine IgG heavy chain. Constitutive splicing of the
hybrid intron was validated using RT–PCR ampliﬁcation
of the spliced product (Supplementary Figure S5).
Surprisingly, Env expression levels were not improved
by inclusion of this upstream intron and mRNA accumu-
lation remained compromised (Figure 4B). Thus U1
snRNA binding to the heterologous SD could not substi-
tute for U1 snRNA binding at SD4 demonstrating that
the local mRNA context of SD4 is important for U1
snRNA enhancement of transcription. To conﬁrm this,
we used the Env GFP reporter, gp140uncGFP, to assess
the ability of U1mut50arm to rescue expression from
the SD4SA7 mutant. Protein expression from the
SD4SA7 mutant was reduced to 42%±17 of wild-type
(Figure 4C), indicating that the heterologous hybrid
intron could not substitute for U1 snRNA binding to
the authentic SD4. Upon co-transfection of the modiﬁed
U1 snRNA, protein expression was rescued to
 77%±11 of wild-type, while the Sm mutant could not
rescue Env expression from the SD4SA7 mutant.
Transfer of the SD4-SA7 intron into a heterologous
context maintains U1 snRNA responsiveness
Binding sites for the SR-proteins SF2/ASF and SRp40
exist upstream of SD4 (50) and may confer dependence
upon U1 snRNA binding on account of their exon deﬁni-
tion role and interaction with the CTD of Pol II (10,12,13).
To test if the SR-binding, exonic sequence confers the
transcriptional requirement for U1 snRNA binding, we
replaced HIV exon sequence with GFP-coding sequence
to make GFP(SD4SA7) (Figure 5A). Insertion of the
SD4-SA7 intron only reduced GFP ﬂuorescence by 20%,
indicating that the intron is spliced accurately and
eﬃciently to produce GFP (Figure 5B, cf. GFP to
GFP(SD4SA7). The small decrease in ﬂuorescence may
be due to retention of the SD4-SA7 intron from ineﬃcient
splicing andthe presence of Rev. The incorporation of SD4
and SA7 mutations (analogous to those in Figure 1B
and C) reduced GFP ﬂuorescence to near background
levels conﬁrming the abolition of splicing [Figure 5B,
GFP(mutSD4SA7)].
The ability of U1 snRNA to increase nuclear accumu-
lation of unspliced mRNA in the context of GFP exons
was examined by northern blotting (Figure 5C). Since
Rev was co-transfected with this construct, unspliced
mRNA could be detected in nuclear-associated ER and
cytoplasmic fractions indicating that Rev, even in the
presence of non-native exonic sequences, can facilitate
the export of unspliced mRNA containing the SD4-SA7
intron. The downward size shift of unspliced mRNA in
the nuclear-associated ER fraction may result from
deadenylation, induced by the nonsense-mediated decay
pathway (51) as the intron contains numerous stop
codons. Nuclear accumulation of unspliced mRNA was
not reduced by the SD4SA7 mutation after being nor-
malized to gapdh mRNA levels (Figure 5D). However,
co-transfection of U1mut50arm with GFP(mutSD4SA7)
resulted in an almost 5-fold increase in nuclear mRNA
accumulation (Figure 5D), indicating that exon sequence
identity is not crucial for U1 snRNA enhancement.
The elongation activator, HIV Tat, can partially rescue
the SD4SA7 mutant expression
HIV is one of the most well characterized viral expression
systems and studies using this virus have lead to key
insights into higher eukaryotic molecular biology (52).
We used the HIV proteins Tat and Rev to probe into
the mechanism of U1 snRNA enhancement of expression.
Tat activates elongation from the HIV LTR promoter by
interacting with the trans-activation response (TAR)
element in the ﬁrst 50nt of the HIV transcript. This inter-
action enhances the binding of Cyclin T1 of the P-TEFb
complex to TAR which allows phosphorylation of the
CTD of Pol II at Ser 2. In contrast to Tat, Rev acts
post-transcription to allow the export of unspliced env
mRNA to the cytoplasm for translation. We titrated
these two regulatory proteins to assess their role in the
expression of Env in the absence of U1 snRNA
recruitment by splicing signals. Increasing concentrations
of Tat increased expression from the SD4SA7 mutant con-
struct relative to WT.R38 from 9.5% at 1ng, up to 45% at
Nucleic Acids Research,2010, Vol.38, No. 9 3047125ng (Figure 6A). In contrast, Rev did not show such a
dose response with relative expression compared to the
WT.R38 construct remaining below 26.5%. Furthermore,
Tat was able to trans-activate the SD4SA7 mutant more
than 200-fold compared to only 18-fold for WT.R38
(Supplementary Figure S6). Thus the elongation activator
Tat is able to partially replace the activity of U1 snRNA
binding, suggesting that U1 snRNA may inﬂuence
transcriptional elongation.
We investigated this further by using a Tat mutant,
K51A, which removes an acetylation site at lysine (K)
51 but still allows eﬃcient trans-activation of a simple
LTR-GFP reporter (data not shown). Acetylation at
K50 and K51 in the RNA-binding domain of Tat is per-
formed by p300 and permits dissociation of the
Tat:TAR:Cyclin T1 complex (53) (Figure 6B). When Tat
K51A was used to trans-activate transcription of the
WT.R38 construct, there was no signiﬁcant change in
reporter expression (Figure 6C). In contrast, when Tat
K51A was co-transfected with the SD4SA7 mutant,
expression was reduced by 87%±4.3. Thus, in the
absence of U1 snRNA binding, acetylation at lysine 51
is critical for transcription through the distal intron
sequence.
Figure 4. The requirement for U1 snRNA binding is independent of promoter and an upstream artiﬁcial intron. (A) The promoter does not alter the
requirement for U1 snRNA recruitment. pHIV-Env and pCMV-Env are shown with their promoter, 50 exon and intron sequence drawn to scale.
Cells were transfected with these constructs containing either the WT.R38 or mutSD4SA7 mutations, 20ng of pCMV-Tat for the pHIV construct
and 100ng of pCMV-Rev, harvested for protein and Western blotted for Env (gp160) and b-actin. (B) An upstream artiﬁcial intron cannot rescue
protein or mRNA expression from mutSD4SA7. pCMV-Intron-Env is shown drawn to scale relative to pHIV-Env and pCMV-Env. Cells were
transfected with either WT.R38 or mutSD4SA7 along with 100ng of pCMV-Rev. The northern probe was made using Odp.1126 and Odp.92 (C)U 1
snRNA rescue of mutSD4SA7 is independent of the promoter and an upstream intron. The GFP reporter from Figure 3B was expressed from
pCMV-Intron as shown. Values represent the GFP ﬂuorescence from the reporter shown above, normalized to WT.R38 plus U1 50arm WT. The Sm
U1 snRNA mutant was used as a negative control. Error bars represent the standard deviation of the mean for three transfections performed on
diﬀerent days.
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The unusual dependence upon U1 snRNA binding for
eﬃcient expression from HIV-derived cDNA constructs
has been a long-standing issue and its examination here
provides several new insights. First, the trans-rescue by
pUCB-U1 allowed us to determine elements within U1
snRNA which permitted an increase in transcription.
Fortunately, the secondary structure and binding sites
Figure 6. Tat acetylation is important for transcription in the absence
of U1 snRNA recruitment. (A) Tat and not Rev partially replaced the
need to bind U1. gp140uncGFP with indicated mutations reported a
dose-response from pCMV-Tat and pCMV-Rev. Values represent
the percentage expression level of mutSD4SA7 relative to WT.R38.
(B) Post-translational modiﬁcations of Tat and locations of acetylation
sites. Lysine 51 (K51) in the RNA-binding domain is acetylated by
p300. (C) Lysine 51 is important only for expression in the absence
of U1 snRNA recruitment by splicing signals. Tat mutant K51A was
tested for trans-activation activity by co-transfection with WT.R38 or
mutSD4SA7. Protein expression was assessed by FACS analysis of
gp140uncGFP. Error bars represent the standard deviation of the
mean of ﬁve independent transfections.
Figure 5. U1 snRNA transcriptional enhancement depends on in
the intron sequence following the U1-bound SD. (A) Plasmid
map of the GFP and GFP(SD4SA7) constructs. (B) The SD4-SA7
intron is eﬃciently and accurately spliced from GFP(SD4SA7)
to produce GFP protein. Fluorescence from GFP, GFP(SD4SA7)
and GFP(mutSD4SA7) constructs was measured using FACS.
GFP(mutSD4SA7) contains the mutations outlined in Figure 1B
and C and these transfections included 100ng of pCMV-Rev. (C)U 1
snRNA increases the nuclear accumulation of unspliced mRNA in the
absence of HIV exonic sequence. Cells were transfected with the
indicated constructs, including 100ng of pCMV-Rev, and fractionated
into nuclear (N), nuclear-associated rough ER (R) and cytoplasmic (C)
fractions. RNA was northern blotted using a probe to GFP made from
Odp. 445 and Odp.1250. The purity of fractions was assessed by
probing for U6 snRNA. (D) Nuclear unspliced mRNA band intensities
were quantiﬁed from the blot shown above and normalized to the band
intensities of gapdh. Values represent the fold diﬀerence in mRNA
levels expressed compared to GFPi plus U1WT50arm.
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in vitro (44,45,48,49). A deletion of the entire stem loop
II ablated rescue of mutSD4SA7 by the U1mut50arm. The
crystal structure of U1 snRNP shows stem loop II
protruding from the globular Sm core (54). Additionally,
stem loop II is non-essential for E complex formation and
in vitro splicing (55), but essential for interaction with
Cyclin H of the TFIIH complex which increased the
kinase activity of CDK7 against the CTD (24). As muta-
tions to the binding site for U1A on loop II did not
signiﬁcantly inhibit U1-rescue, stem loop II (when
unbound to U1A) may be free to interact with Cyclin H,
Cyclin T1 [perhaps through the TAR recognition motif
(56)] or indeed other components of the transcription
machinery. A precedent for regulation of CTD kinase
activity by non-coding RNA already exists in 7SK
snRNP sequestration of the inactive P-TEFb (57).
Gene expression is predominantly regulated by tran-
scription factor recruitment to sequence-speciﬁc DNA
elements in the promoter which stimulate initiation (58).
The promoter can also aﬀect the pattern of alternative
splicing (59), thus presenting a likely element connecting
U1 snRNA and transcription. However, swapping the
HIV promoter with a CMV promoter did not alter the
inﬂuence of U1 snRNA on transcription so determinants
of U1-dependence must exist within the transcript. The
inclusion of a heterologous upstream intron however
also did not change the requirement for U1 snRNA
recruitment to SD4. Thus U1 engagement alone is insuf-
ﬁcient to mediate enhancement of transcription and the
spatial or temporal proximity to the SD4-SA7 intron
may be crucial. Evidence for intron speciﬁc regulation of
transcription by splicing was shown by the SC35
depletion-induced Pol II pausing in an intron of mouse
Ptbp1 but not the closely related Ptb2 gene (21). Also, a
heterologous intron capable of directing eﬃcient splicing
does not increase P-TEFb-dependent elongation of the
intron-less U2 snRNA (23). These data indicate that
gene speciﬁc elements mediate the connection between
transcription and splicing and points to the existence of
an intrinsic block to transcription elongation in the
SD4-SA7 intron which is counteracted by U1 snRNA
binding to SD4. This is supported by the maintenance of
U1 snRNA responsiveness upon moving the SD4-SA7
intron to a heterologous context.
The signiﬁcance of post-initiation regulation in
eukaryotic gene expression was highlighted by global
ChIP analysis where 75% of human genes contained
initiated Pol II with no detectable transcripts (60).
Furthermore, P-TEFb-dependent pausing was shown
also to occur at late points along the b-actin gene (61).
Transcriptional pausing can be induced by nucleosomes
(62,63), RNA structure (64–66), or the negative elongation
factors such as NELF and DSIF (67). Recent SHAPE
analysis of HIV RNA (68), presents many possible
structured or unstructured regions which could regulate
elongation processivity (65). One described function for
transcriptional pausing is to ensure proper capping of
the transcript (69). A similar mechanism may exist at the
50 border of some introns to aﬀord time for proper
assembly of U1 snRNP complexes.
The transcriptional elongation activator Tat, can
replicate the activity of U1 snRNA binding. An associa-
tion of U1 snRNA with the elongation factor Tat-SF1
may assist in recruitment of P-TEFb (22) akin to Tat
recruitment of P-TEFb through TAR. Recruitment local
to the SD4 site may provide the boost to elongation
required to transcribe the intron. Certainly, mutation of
SD1 in a CMV-driven HIV proviral clone inducing
Tat-dependence (70) lends further evidence for U1
snRNA enhancement of elongation. Mutation of the
acetylation site K51 resulted in a signiﬁcant reduction in
expression speciﬁc to the mutSD4SA7 mutant. Lysines 50
and 51 lie within the TAR-binding domain and when
acetylated, disrupt formation of the Tat:TAR:Cyclin T1
ternary complex leaving Tat free to associate with the
elongating Pol II (71) and/or recruit the histone
acetyltransferase (HAT) PCAF (72). Transcription from
DNA plasmids is enhanced by histone deacetylase inhib-
itors (73) and intron sequence 30 to SD4 is occupied by
nucleosomes in both an integrated HIV-1 genome and a
nuclear episome suggesting primary DNA sequence deter-
mines nucleosome placement in this region (74). It is
possible that both acetylated Tat and U1 snRNA
increase transcription by facilitating passage of Pol II
through a DNA template associated with nucleosomes.
The newly identiﬁed U1-TAF15 snRNP which associates
with chromatin in an RNA-dependent manner provides
preliminary evidence that U1 snRNA may inﬂuence
nucleosomal packaging of DNA (75).
The molecular determinants allowing U1 snRNA
enhancement of transcription are unclear, but the data
presented could result from a transcriptional pause some-
where within the intron, which is overcome by the
recruitment of an Sm-type U1 snRNA with intact stem
loop II to the intron-bordering SD as modelled in
Figure 7. A non-mutually exclusive possibility is that for-
mation of the RNA:RNA helix between U1mut50arm and
mutSD4 neutralizes a transcriptional defect induced by
mutSD4. Given the central role of phosphorylation of
Figure 7. Proposed model for U1 snRNA enhancement of transcrip-
tion. (A) Transcription of pre-mRNA containing the SD4-SA7 intron is
inhibited in the absence of U1 snRNA recruitment by SD4. (B) When
U1 snRNA binds at the SD, transcription through the SD4-SA7 intron
is eﬃcient, possibly due to an increase in the processivity of elongation
via P-TEFb phosphorylation of the Pol II CTD at Serine 2.
3050 Nucleic Acids Research, 2010,Vol.38, No. 9the CTD of Pol II in transcriptional control and the
observed partial rescue of the splice mutant by HIV Tat,
our data also raises the possibility that U1 snRNA–
binding induces an increase in the phosphorylation at
Ser 2, suggesting that U1 snRNA may provide positive
feedback to the elongating Pol II during transcription
through this intron-containing mRNA.
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